Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

Severe cutaneous adverse reactions (SCARs), previously thought to be idiosyncratic or unpredictable, are a deadly form of adverse drug reactions with skin manifestations. Current pharmacogenomic studies of SCARs have made important strides, as the prevention of SCARs, to some extent, appears attaina...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2016-11, Vol.17 (11), p.1890-1890
Main Authors: Su, Shih-Chi, Hung, Shuen-Iu, Fan, Wen-Lang, Dao, Ro-Lan, Chung, Wen-Hung
Format: Article
Language:English
Subjects:
Allopurinol - adverse effects
Anti-HIV Agents - adverse effects
Anticonvulsants - adverse effects
Antigens
Biomarkers - metabolism
Carbamazepine - adverse effects
Dideoxynucleosides - adverse effects
Genetic Markers
Gout Suppressants - adverse effects
HLA-B Antigens - genetics
HLA-B Antigens - immunology
Humans
Inactivation, Metabolic - genetics
Inactivation, Metabolic - immunology
Leukocytes
Pharmacogenetics
Pharmacology
Precision Medicine
Prognosis
Review
Safety-Based Drug Withdrawals
Side effects
Stevens-Johnson Syndrome - etiology
Stevens-Johnson Syndrome - genetics
Stevens-Johnson Syndrome - immunology
Stevens-Johnson Syndrome - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe cutaneous adverse reactions (SCARs), previously thought to be idiosyncratic or unpredictable, are a deadly form of adverse drug reactions with skin manifestations. Current pharmacogenomic studies of SCARs have made important strides, as the prevention of SCARs, to some extent, appears attainable with the identification of genetic variants for genes encoding drug-metabolizing enzymes and human leukocyte antigens (HLAs). Despite the improvement of incidence, a treatment guideline for this devastating condition is still unavailable, highlighting the inadequacy of contemporary accepted therapeutic interventions. As such, prompt withdrawal of causative drugs is believed to be a priority of patient management. In this review, we discuss recent cutting-edge findings concerning the discovery of biomarkers for SCARs and their clinical utilities in the better prediction and early diagnosis of this disease. The knowledge compiled herein provides clues for future investigations on deciphering additional genetic markers for SCARs and the design of clinical trials for the prospective identification of subjects at genetic risk for this condition, ultimately personalizing the medicine.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms17111890